Archive: 2018
Dr. Jill Biden at Medidata NEXT NYC On The Work Ahead For All Of Us
“Let the Beauty of What You Love Be What You Do.” Read More
NEXT Hackathon 2018 Recap
This year’s NEXT NYC conference at Spring Studios was a resounding success—featuring speakers from Medidata, Amazon Web Services, Google Cloud, the Biden Cancer Initiative (with former Second Lady Jill Biden herself), and much more—catering to a diverse audience of over one thousand life sciences professionals during the two-day event. Read More
Closing the Gap on Gender Parity in the Workforce
"With the new day comes new strength and new thoughts." — Eleanor Roosevelt Read More
Need to Accelerate Research In the Face of Trial Complexity? Consider a Unified Data Strategy
The stakes for delays in clinical research are high. Read More
Put the Patient First In Clinical Trial Design
"How many of your colleagues can describe and visualize the actual patient experience?" Read More
Medidata acquires SHYFT: Powering the Digital Transformation for Life Sciences
Digital transformation: this is one of the hottest topics in our industry today, creating both opportunities and challenges for our customers. For pharmaceutical, biotech, and medical device companies, the promise of making data-driven, insights-led decisions in real-time means getting the right treatments to the right patients at the right time. To truly realize this potential, they need to rely on combined insights from both clinical and commercial data. Read More
The Rewards and Pitfalls of Orphan Drug Development: PhaseBio, Medidata’s 1,000th Customer, Rises to the Challenge
PhaseBio—a clinical-stage biopharma company developing improved biotherapeutics for orphan diseases, with an initial focus on cardiopulmonary disorders—has the distinction of being Medidata's 1,000th customer. Read More
Taking the Risk Out of Clinical Trial Submissions using AI
So far Edge Trial Assurance has been used in 30 trials. It has detected 50-75 data anomalies in every single trial. Read More
Five Key Data Quality Issues To De-risk Your Trial
When it comes to submitting new drug applications to FDA, it’s safe to assume that the prospect of receiving a complete response letter keeps pharma executives up at night. The risks associated with regulatory submission can have a substantial impact on a business, and approval delays due to data issues can cost a company millions. As a former FDA reviewer, I’ve seen just about everything when it comes to data quality issues that can derail drug approvals. Luckily, today these kinds of risks can be mitigated using sophisticated data analytics. Read More
One Place: Transform Precision Medicine with Medidata Clinical Cloud
Nearly 20 years ago Medidata was built around modernizing data capture and management, which ultimately became Rave. Today, we can confidently say we’re so much more than that. Read More